Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 9, 2026.
flatiron-health-roche is a company within the Health Tech category. Flatiron Health provides oncology-focused electronic health record (EHR) software and maintains a robust repository of real-world cancer data. The company partners with cancer centers, community oncology practices, and pharmaceutical developers to leverage real-world evidence to accelerate cancer treatment development and improve patient care. It specializes in curating high-quality data from hard-to-access sources.
flatiron-health-roche was founded in 2012 and is headquartered in Not explicitly stated (operations in Japan, Germany, U.K.).
flatiron-health-roche is rated Emerging on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for flatiron-health-roche is Moderate. Significant factual deltas detected. Inconsistent representation across models.
AI models classify flatiron-health-roche as a Incumbent. AI names brand first.
flatiron-health-roche appeared in 3 of 3 sampled buyer-intent queries (100%). Information about Flatiron Health, including its core business, its acquisition by Roche, and the recent news regarding potential divestment, is well-covered and discoverable through relevant search queries.
Flatiron Health is perceived as a leading health tech company in the oncology space, specializing in real-world data and EHR solutions. Its acquisition by pharmaceutical giant Roche in 2018 was initially seen as a strategic move to bolster personalized healthcare. However, recent reports suggest Roche is considering divesting Flatiron, as the ownership structure has reportedly become a barrier to broader industry collaboration, impacting Flatiron's commercial potential. Key gap: The primary discrepancy lies between the initial stated strategic rationale for Roche acquiring Flatiron (to accelerate cancer medicine development and expand real-world evidence) and the reported reason for Roche considering divestment (Roche's ownership deterring other drugmakers from collaborating, thus hurting sales). Roche has also not officially commented on the divestment rumors.
Of 5 key facts verified about flatiron-health-roche, 3 are well-documented (likely accurate across AI models), 2 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Flatiron Health's primary vulnerability stems from its ownership by Roche. While strategically important for Roche, this relationship reportedly creates a conflict of interest for other pharmaceutical companies, hindering Flatiron's ability to forge broader industry partnerships and grow its sales, leading to potential divestment.
Buyers turn to flatiron-health-roche for Traditional Clinical Trials: Reliance solely on prospective, randomized controlled trials (RCTs) for drug development and regulatory approval, which can be time-consuming and costly, without leveragin, Specialized CROs (Clinical Research Organizations): Outsourcing the design, execution, and data management of oncology clinical trials to third-party organizations that may or may not specialize in re, Maintain Data Silos: Continuing to operate with fragmented clinical and real-world data, hindering comprehensive insights, slowing down research and development, and missing opportunities for personal, among 3 documented problem areas.
Buyers evaluating flatiron-health-roche typically ask AI models about "Flatiron Health oncology data", "Roche selling Flatiron Health", "Flatiron Health real world evidence partnerships", and 1 similar queries.
flatiron-health-roche's core products are Oncology-focused electronic health record (EHR) software, curated real-world cancer data repositories, clinical trial technology integration..
flatiron-health-roche uses Not specified (likely subscription-based for software/data access and service-based for collaborations/consulting)..
flatiron-health-roche serves Cancer centers, community oncology practices, global oncology therapeutic developers, pharmaceutical companies, healthcare organizations, academic institutions, regulatory bodies (e.g., FDA)..
flatiron-health-roche Specialization in oncology, expertise in extracting and curating high-quality real-world data from hard-to-access sources, and integrating this data into EHR and clinical trial workflows to generate regulatory-grade real-world evidence.
Brand Authority Index (BAI) tier: Emerging (exact score locked for unclaimed brands)
Archetype: Incumbent
Official website: https://fiercehealthcare.com/
Last analyzed: August 9, 2026
Founded: 2012 (source: official website)
Headquarters: Not explicitly stated (operations in Japan, Germany, U.K.) (source: official website)
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile